NIH RELEASES MPOX RESEARCH AGENDA

The National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), has revealed its updated priorities for research on mpox. This initiative is intended to enhance our comprehension of the virus and improve methods for detection, treatment, and prevention.

Key Objectives:
1. Virus Biology: Increase understanding of all mpox virus clades, including transmission and immune system responses.
2. Vaccine Development: Evaluate the current vaccine dosing regimens and develop new vaccine concepts to optimize the supply.
3. Treatment Advancement: Improve existing treatments and develop novel approaches, including antivirals and monoclonal antibodies.
4. Detection Strategies: Support the development of virus detection methods to enhance clinical care and epidemiological surveillance.

Background on Mpox:

  • The first human case was recorded in 1970 in the Democratic Republic of the Congo
  • Endemic in central and western Africa
  • Two identified clades:
    • Clade I (Central Africa): Can cause severe illness
    • Clade II (West Africa): Generally milder, responsible for the 2022 global outbreak

Vulnerable Groups:

  • People with compromised immune systems
  • Children
  • Pregnant individuals

NIAID’s Approach:
NIAID is collaborating with U.S. and international partners to address the current pox outbreak and protect global public health. The institute will utilize both domestic and international
research infrastructures to achieve its objectives.

For more information, visit the NIAID website.